Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
In June 2022, Enosis collaborated with the Swinburne University of Technology in Australia, announcing positive results from the world’s first study on the synergistic application of VR in psychedelics.
The preliminary results showed that Enosis’ bespoke VR scenarios, combined with a guided psychedelic experience, generated high levels of acceptance and satisfaction. The positive results from this first study have led Enosis’ to begin offering VR scenarios with psychedelic-assisted therapy inside OVID Clinics.
Enosis has now partnered with OVID Clinics and the MIND Foundation – a European non-profit science and education organization that promotes psychedelic research and therapy – to implement the world’s first in-clinic application of VR with psychedelic-assisted therapy. The Berlin-based healthcare services provider that delivers integration-focused and psychedelic-based psychotherapies through its network of clinics, OVID Clinics, has begun offering its patients the opportunity to receive psychedelic-assisted psychotherapy integrated with Enosis’ science-backed virtual technology protocols.
Co-founder of Enosis Therapeutics, Agnieszka D. Sekula, said: “The Enosis team is honoured to partner with OVID Clinics and the MIND Foundation to commence the first in-clinic application of our VR protocols as an adjunct to psychedelic-assisted psychotherapy.
“Enhancing patient accessibility to our VR experiences remains our top priority and we are excited to bring this novel treatment to patients in need.
“Together with the OVID team, our focus is to achieve positive patient outcomes and longer-lasting therapeutic benefits for patients battling mental health illnesses.”
Beyond offering the in-clinic protocol in Berlin, Enosis and OVID will be gathering data for a research collaboration aiming to investigate the synergistic effects of psychedelic and digital interventions in hopes that the results demonstrate better therapeutic patient outcomes and enhance overall patient wellbeing.
Co-founder and CEO of OVID Clinics, Sergio Pérez Rosal, commented: “At OVID Clinics, we believe in a personalised, evidence-based, medical and psychotherapeutic approach tailored to the patients’ needs.
“We recognise the value of Enosis´ VR technologies in the integration process following psychedelic therapy.
“We are convinced that this partnership will help innovate the field by shifting the focus from the psychedelic substance to the psychedelic experience and its integration, supporting patients in every step of the way through their journey into well-being.”
